We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 19.50
Ask: 21.00
Change: 0.45 (2.31%)
Spread: 1.50 (7.692%)
Open: 19.95
High: 20.25
Low: 19.50
Prev. Close: 19.50
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

H1 Update and Updated Loan Facilities

20 Jul 2023 07:00

RNS Number : 5782G
Iofina PLC
20 July 2023
 

 

 

 

20 July 2023

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM:IOF)

 

H1 Update and Updated Loan Facilities

 

Iofina plc (AIM:IOF), specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update on H1 2023 (the "Period") iodine production as well as an update on its loan facilities.

 

H1 2023 update

 

During the first half of 2023, Iofina Resources produced 241.5 metric tonnes ("MT") of crystalline iodine from its five IOsorb® plants in NW Oklahoma, within the projected range of 235-250 MT for the Period. This was an increase of 7.5 MT compared to H1 2022. 

 

With IO#9 switched on in June and working through its start-up phases and concentrating iodide, the Company anticipates a significant increase in H2 2023 crystalline iodine production totalling between 325-350 MT (H2 2022: 282 MT). This estimated production range is larger than normal as IO#9 continues to ramp up brine intake and is optimising parameters for its crystalline iodine production. The new plant will be contributing to the Group's total crystalline iodine production from this month.

 

The Company notes that the required configuration of IO#9 resulted in additional equipment and installation costs compared to other IOsorb® plants, which increased total expenditure including reused equipment to $5.5m. Future IOsorb® plant costs are anticipated to be less moving forward. Construction of IO#9 was funded entirely by cash generated from operations.

 

Iofina has continued to see strong demand for its crystalline iodine and derivative chemical products. Spot iodine prices have remained steady near $70/kg throughout the period, with iodine demand for use in X-ray contrast media and pharmaceuticals applications particularly strong. The Company expects these price levels to continue through the second half of the year.

 

Loan Facilities

 

The Company has recently renegotiated its undrawn loan facilities, securing a lower interest rate on agreements arranged last year, as follows:

 

a) The $2.7 million and $1.66 million term loans, which had not been utilized by Iofina, have been replaced by a $4 million term loan with a drawdown period open now through to July 1, 2024 to be used for IO#10 expenditures and other Capex projects as appropriate. A seven-year term begins from July 1, 2024 with interest payable during the drawdown period. The interest rate has been reduced from 2.4% to 2.11% plus SOFR (1 month Secured Overnight Financing Rate) subject to a minimum 1%.

 

b) The $6 million revolving line of credit has been extended by a year to 16 September 2025. The interest rate has been reduced from 2.4% to 2.11% plus SOFR subject to a minimum 1%. Iofina is currently not drawing on this line of credit. 

 

 

Commenting on the first half of the year, President and CEO of Iofina Dr. Tom Becker, stated: 

"I'm pleased to report on another successful period, with the completion of the IO#9 plant being the key milestone of the first half. With the ramp-up of IO#9 progressing, we are on course to deliver a considerable uplift in second-half production. Importantly, demand for our products remains high and we are benefiting from the iodine spot price maintaining its $70/kg level.

 

"Our discussions with prospective partners for IO#10 continue to move forward and we will provide a detailed update once an agreement has been reached. H1 has progressed well for the Group and the Board is looking forward to the second half of 2023."

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Patrick Dolaghan/Andrew Potts

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Financial Adviser:

Kingsley Wilson

Chrystal Capital Partners LLP

Tel: +44 (0)20 7850 4761

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah/Jazmine Clemens

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM:IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

 

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical will be celebrating its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGMNRLMGFZM
Date   Source Headline
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.